CY1119840T1 - Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων - Google Patents

Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων

Info

Publication number
CY1119840T1
CY1119840T1 CY20181100095T CY181100095T CY1119840T1 CY 1119840 T1 CY1119840 T1 CY 1119840T1 CY 20181100095 T CY20181100095 T CY 20181100095T CY 181100095 T CY181100095 T CY 181100095T CY 1119840 T1 CY1119840 T1 CY 1119840T1
Authority
CY
Cyprus
Prior art keywords
sources
cyclically substituted
prophylaxis
treatment
disorders
Prior art date
Application number
CY20181100095T
Other languages
English (en)
Inventor
Chantal FÜRSTNER
Jens Ackerstaff
Alexander Straub
Heinrich Meier
Hanna Tinel
Katja Zimmermann
Adrian Tersteegen
Dmitry Zubov
Reimund Kast
Jens Schamberger
Martina SCHÄFER
Kirsten BÖRNGEN
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of CY1119840T1 publication Critical patent/CY1119840T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα αίτηση αφορά νέα δικυκλικώς υποκατεστημένα παράγωγα ουρακίλης, τη χρήση αυτών μεμονωμένα ή σε συνδυασμούς για την θεραπευτική αγωγή και/ή προφύλαξη των περιφερικών κυκλοφορικών διαταραχών, καθώς και τη χρήση τους για την παραγωγή φαρμάκων για την θεραπευτική αγωγή και/ή προφύλαξη των περιφερικών κυκλοφορικών διαταραχών.
CY20181100095T 2012-05-09 2018-01-24 Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων CY1119840T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12167231 2012-05-09
EP16154186.7A EP3045456B1 (de) 2012-05-09 2013-05-03 Bicyclisch-substituierte uracile und ihre verwendung
EP13720407.9A EP2847190B1 (de) 2012-05-09 2013-05-03 Bicyclisch-substituierte uracile und ihre verwendung

Publications (1)

Publication Number Publication Date
CY1119840T1 true CY1119840T1 (el) 2018-06-27

Family

ID=48289199

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100636T CY1118900T1 (el) 2012-05-09 2016-07-06 Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
CY20181100095T CY1119840T1 (el) 2012-05-09 2018-01-24 Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161100636T CY1118900T1 (el) 2012-05-09 2016-07-06 Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων

Country Status (44)

Country Link
US (5) US9481672B2 (el)
EP (2) EP3045456B1 (el)
JP (2) JP6141414B2 (el)
KR (1) KR102083281B1 (el)
CN (2) CN104395310B (el)
AP (1) AP2014008096A0 (el)
AR (1) AR090994A1 (el)
AU (2) AU2013258223B2 (el)
BR (1) BR112014028086B1 (el)
CA (1) CA2872906C (el)
CL (1) CL2014003031A1 (el)
CO (1) CO7131375A2 (el)
CR (1) CR20140513A (el)
CU (1) CU20140129A7 (el)
CY (2) CY1118900T1 (el)
DK (2) DK2847190T3 (el)
DO (1) DOP2014000255A (el)
EA (2) EA030383B9 (el)
EC (1) ECSP14026138A (el)
ES (2) ES2581537T3 (el)
HK (1) HK1202873A1 (el)
HR (2) HRP20160796T1 (el)
HU (2) HUE029366T2 (el)
IL (2) IL235438A (el)
JO (1) JO3290B1 (el)
LT (1) LT3045456T (el)
MX (2) MX357712B (el)
MY (1) MY181828A (el)
NO (1) NO3045456T3 (el)
NZ (1) NZ701700A (el)
PE (1) PE20142301A1 (el)
PH (1) PH12014502496A1 (el)
PL (2) PL2847190T3 (el)
PT (2) PT3045456T (el)
RS (2) RS54901B1 (el)
SA (1) SA113340533B1 (el)
SG (1) SG10202003175QA (el)
SI (2) SI3045456T1 (el)
TN (1) TN2014000470A1 (el)
TW (2) TWI579278B (el)
UA (1) UA112897C2 (el)
UY (1) UY34797A (el)
WO (1) WO2013167495A1 (el)
ZA (1) ZA201408146B (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
ME02907B (me) * 2013-11-08 2018-04-20 Bayer Pharma AG Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksilne kisjeline
JP2016535769A (ja) * 2013-11-08 2016-11-17 バイエル ファーマ アクチエンゲゼルシャフト キマーゼ阻害薬としての置換されているウラシル類
CN105899500A (zh) * 2013-11-08 2016-08-24 拜耳医药股份有限公司 取代的1，2，4-三嗪-3，5-二酮及其作为类糜蛋白酶抑制剂的用途
EP3066098A1 (de) 2013-11-08 2016-09-14 Bayer Pharma Aktiengesellschaft Substituierte uracile und ihre verwendung
WO2017162661A1 (en) 2016-03-22 2017-09-28 Bayer Pharma Aktiengesellschaft 1h-benzo[de]isoquinoline-1,3(2h)-diones
EP3338780A1 (de) * 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
EP3615031A1 (en) 2017-04-27 2020-03-04 Bayer Aktiengesellschaft Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
BR112020022340A2 (pt) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
CN110229067A (zh) * 2019-06-05 2019-09-13 南京焕然生物科技有限公司 一种2-氨基茚制备方法
WO2021000933A1 (zh) * 2019-07-03 2021-01-07 南京明德新药研发有限公司 作为糜酶抑制剂的嘧啶酮类化合物及其应用
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CN111440141A (zh) * 2020-05-20 2020-07-24 安徽泽升科技有限公司 一种羟甲基取代芳杂环类化合物的制备方法
WO2022135502A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 多取代的尿嘧啶衍生物及其用途
CN114685472B (zh) * 2020-12-25 2024-04-26 广东东阳光药业股份有限公司 多取代的尿嘧啶衍生物及其用途
WO2022135534A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 取代的含氮双环化合物及其用途
TW202342061A (zh) * 2021-12-06 2023-11-01 美商普萊萃歐治療公司 Ｌｏｎｐ１抑制劑、用途及方法
WO2023194222A1 (en) * 2022-04-05 2023-10-12 Socpra Sciences Santé Humaines S.E.C. Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
WO2001017980A1 (fr) 1999-09-03 2001-03-15 Ajinomoto Co., Inc. Nouveaux procedes de preparation de derives d'oxazepine
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
GB0021315D0 (en) * 2000-08-30 2000-10-18 Dainippon Pharmaceutical Co Heterocyclic compounds and intermediates thereof
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
JP2003017508A (ja) 2001-07-05 2003-01-17 Nec Corp 電界効果トランジスタ
AR038536A1 (es) 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2003342265A (ja) * 2002-05-22 2003-12-03 Senju Pharmaceut Co Ltd トリアゾリジン誘導体およびその医薬用途
WO2004052858A2 (en) 2002-12-06 2004-06-24 Eli Lilly And Company Inhibitors of monoamine uptake
WO2005018672A1 (ja) * 2003-08-22 2005-03-03 Teijin Pharma Limited キマーゼ阻害剤を有効成分として含有する薬剤
DE102004004928A1 (de) 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
CA2559733C (en) 2004-03-26 2014-05-13 Methylgene Inc. Inhibitors of histone deacetylase
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
JP5197016B2 (ja) 2004-12-23 2013-05-15 デシファラ ファーマスーティカルズ， エルエルシー 酵素モジュレータ及び治療
US7745451B2 (en) 2005-05-04 2010-06-29 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions
WO2007007161A2 (en) * 2005-07-08 2007-01-18 Orchid Research Laboratories Limited Novel bio-active derivatives
WO2007120339A1 (en) 2005-12-19 2007-10-25 Genentech, Inc. Pyrimidine kinase inhibitors
ATE443061T1 (de) 2006-02-14 2009-10-15 Pfizer Prod Inc Benzoxazinon- und benzoxazepinonoxazolidinone als antibakterielle mittel
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
GB0622472D0 (en) 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
CA2683785A1 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
NZ585348A (en) 2007-10-19 2012-02-24 Boehringer Ingelheim Int Heterocycle-substituted piperazino-dihydrothienopyrimidines
KR20130029116A (ko) * 2008-05-05 2013-03-21 머크 샤프 앤드 돔 리미티드 레닌 억제제로서의 3,4-치환된 피페리딘 유도체
EP2289868B1 (en) 2008-06-25 2014-08-13 Daiichi Sankyo Company, Limited Carboxylic acid compound
DE102008030091B4 (de) 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань

Also Published As

Publication number Publication date
HK1202873A1 (en) 2015-10-09
EA201492040A1 (ru) 2015-12-30
BR112014028086B1 (pt) 2021-09-21
CU20140129A7 (es) 2015-02-26
JP6367421B2 (ja) 2018-08-01
AU2013258223B2 (en) 2017-11-09
PH12014502496B1 (en) 2015-01-12
TW201406744A (zh) 2014-02-16
JP6141414B2 (ja) 2017-06-07
AU2017265047B2 (en) 2019-04-18
UY34797A (es) 2013-11-29
SA113340533B1 (ar) 2015-10-12
PL3045456T3 (pl) 2018-03-30
US20150148340A1 (en) 2015-05-28
US20180256576A1 (en) 2018-09-13
EP2847190B1 (de) 2016-04-06
ES2581537T3 (es) 2016-09-06
SI2847190T1 (sl) 2016-08-31
CN104395310B (zh) 2017-05-03
MX367599B (es) 2019-08-28
CN104395310A (zh) 2015-03-04
HUE029366T2 (en) 2017-02-28
BR112014028086A2 (pt) 2020-12-01
US9949977B2 (en) 2018-04-24
MX357712B (es) 2018-07-20
US9481672B2 (en) 2016-11-01
NZ701700A (en) 2016-09-30
TWI579278B (zh) 2017-04-21
AR090994A1 (es) 2014-12-30
RS54901B1 (sr) 2016-10-31
US20170020875A1 (en) 2017-01-26
CR20140513A (es) 2014-12-02
EP2847190A1 (de) 2015-03-18
IL253950A0 (en) 2017-10-31
HUE035462T2 (en) 2018-05-02
ECSP14026138A (es) 2015-12-31
SG10202003175QA (en) 2020-05-28
EA031222B1 (ru) 2018-12-28
TN2014000470A1 (en) 2016-03-30
WO2013167495A1 (de) 2013-11-14
AU2017265047A1 (en) 2017-12-14
PH12014502496A1 (en) 2015-01-12
IL235438A (en) 2017-08-31
EA030383B9 (ru) 2018-12-28
JP2017160242A (ja) 2017-09-14
RS56784B1 (sr) 2018-04-30
EP3045456A1 (de) 2016-07-20
TWI635085B (zh) 2018-09-11
HRP20160796T1 (hr) 2016-08-12
JP2015516000A (ja) 2015-06-04
KR102083281B1 (ko) 2020-05-29
US20170020876A1 (en) 2017-01-26
MX2014013571A (es) 2014-12-08
TW201734007A (zh) 2017-10-01
CA2872906C (en) 2020-08-04
NO3045456T3 (el) 2018-03-24
AU2013258223A1 (en) 2014-11-27
UA112897C2 (uk) 2016-11-10
DK3045456T3 (da) 2018-01-29
DK2847190T3 (en) 2016-07-25
PE20142301A1 (es) 2014-12-19
US9949978B2 (en) 2018-04-24
CY1118900T1 (el) 2018-01-10
EP3045456B1 (de) 2017-10-25
DOP2014000255A (es) 2015-02-27
KR20150016548A (ko) 2015-02-12
CO7131375A2 (es) 2014-12-01
CN106983751A (zh) 2017-07-28
LT3045456T (lt) 2018-02-12
SI3045456T1 (en) 2018-03-30
CA2872906A1 (en) 2013-11-14
PL2847190T3 (pl) 2016-12-30
EA201790032A1 (ru) 2017-05-31
PT2847190T (pt) 2016-07-14
JO3290B1 (ar) 2018-09-16
CL2014003031A1 (es) 2015-03-06
EA030383B1 (ru) 2018-07-31
US20200061063A1 (en) 2020-02-27
MY181828A (en) 2021-01-08
AP2014008096A0 (en) 2014-12-31
ZA201408146B (en) 2017-01-25
ES2657315T3 (es) 2018-03-02
CN106983751B (zh) 2020-01-07
PT3045456T (pt) 2018-01-30
IL253950B (en) 2019-07-31
US10300062B2 (en) 2019-05-28
HRP20180125T1 (hr) 2018-02-23

Similar Documents

Publication Publication Date Title
CY1119840T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
CY1124446T1 (el) Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1125436T1 (el) Αναστολεις dna-pk
CY1119123T1 (el) Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους
CY1120421T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
CY1123996T1 (el) Υποκατεστημενα παραγωγα οξοπυριδινης
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
EA201692109A1 (ru) Варианты антител к фактору d и их применение
UY36171A (es) Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa
CY1124492T1 (el) 7-υποκατεστημενα 1-αρυλο-ναφθυριδιν-3-καρβοξαμιδια και η χρηση αυτων
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CY1123284T1 (el) Συνθεση που περιλαμβανει υδροκορτιζονη
SG10201908881PA (en) Fused bicyclic compounds for the treatment of disease
DK3419673T3 (da) Genterapi til behandling af sygdom i nethindens tapceller
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
CY1117577T1 (el) Υποκατεστημενα φουρανοκαρβοξαμιδια και χρηση αυτων
CY1122708T1 (el) Ενωσεις οξα-διαζασπειρο με δραση εναντι του πονου